What is the 13F Pro Quality Score for ICCC?

13F Pro ranks IMMUCELL CORP /DE/ (ICCC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ICCC's current score at https://13fpro.ai/research/ICCC (free sign-up required for the full ranking).

Where does 13F Pro source ICCC data?

All IMMUCELL CORP /DE/ fundamentals and ownership data come directly from SEC EDGAR. IMMUCELL CORP /DE/ files with the SEC under CIK 811641. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ICCC in?

IMMUCELL CORP /DE/ (ICCC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ICCC research updated on 13F Pro?

ICCC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IMMUCELL CORP /DE/(ICCC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 811641 ICCC stock profile & AI dashboard →

13F Pro Quality Score

64.6/100

Rank #628 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

85.0/100

Profitability

80.0/100

Balance Sheet

84.2/100

Earnings Quality

30.0/100

Free Cash Flow

71.1/100

Institutional Flow

59.1/100

Revenue Scale

7.5/100

Dilution Risk

54.4/100

ICCC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IMMUCELL CORP /DE/ (ICCC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICCC at 64.6/100 on a 32-signal composite quality model, placing it at rank #628 of 2,879 stocks — the top 25% of the AI-ranked universe. ICCC scores in the top quartile across revenue growth (85.0), balance sheet strength (84.2), profitability (80.0). Areas of concern include revenue scale (7.5) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), IMMUCELL CORP /DE/ reports quarterly revenue of $10.4M, net income of $1.9M, free cash flow of $3.4M. Top institutional holders of ICCC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. ICCC trades on the Nasdaq exchange and files with the SEC under CIK 811641. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUCELL CORP /DE/ directly from SEC EDGAR. IMMUCELL CORP /DE/'s 13F Pro composite quality score has ranged between 19 and 65 since 2025, currently 64.6 — an improving long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about IMMUCELL CORP /DE/

Quirks, history, and lore behind ICCC — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. animal health company · listed on Nasdaq · headquartered in Maine.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is decidedly micro-cap territory, serving a niche market most investors have never thought about.
3
The History
Founded in the 1980s, the company carved out a narrow lane in veterinary biologics and pharmaceuticals, focusing almost entirely on dairy and beef cattle.
4
The Secret
Its core mission is fighting mastitis — a costly bacterial udder infection — which costs the dairy industry billions of dollars annually worldwide.
5
The Lore
Its flagship product is one of the very few FDA-approved treatments specifically targeting staph aureus mastitis in dairy cows — a remarkably specific moat for a tiny company.
6
The Giveaway
Ticker ICCC, based in Portland, Maine — this little biotech's whole identity is keeping dairy cows healthy, one udder at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$10.4M

Net Income

Q1 2026

$1.9M

Free Cash Flow

Q1 2026

$3.4M

D/E Ratio

Q1 2026

0.35

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+48.9% YoY

$27.6MFY 2025

FY18 $11.0MFY19 $13.7MFY22 $18.6MFY25 $27.6M

Net Income

+58.3% YoY

$-1.0MFY 2025

FY18 $-2.3MFY19 $-1.3MFY22 $-2.5MFY25 $-1.0M

Operating Income

+171.7% YoY

$1.6MFY 2025

FY18 $-1.4MFY19 $-953.9KFY22 $-2.3MFY25 $1.6M

EPS (Diluted)

+62.5% YoY

$-0.12FY 2025

FY18 $-0.42FY19 $-0.19FY22 $-0.32FY25 $-0.12

Total Assets

-5.2% YoY

$42.5MFY 2025

FY18 $32.7MFY19 $38.7MFY22 $44.9MFY25 $42.5M

Total Debt

-46.9% YoY

$10.7MFY 2025

FY18 $18.6MFY19 $16.9MFY22 $20.2MFY25 $10.7M

Op. Cash Flow

+260.3% YoY

$2.5MFY 2025

FY18 $-373.4KFY19 $233.5KFY22 $-1.5MFY25 $2.5M

Metric	FY 2025	FY 2022	FY 2019	FY 2018	FY 2017	FY 2015
Revenue	$27.6M +48.9%	$18.6M +35.3%	$13.7M +24.9%	$11.0M +5.3%	$10.4M +2.0%	$10.2M
Net Income	$-1.0M +58.3%	$-2.5M -92.5%	$-1.3M +44.2%	$-2.3M -1280.7%	$-168.1K -113.9%	$1.2M
Operating Income	$1.6M +171.7%	$-2.3M -141.0%	$-953.9K +34.1%	$-1.4M -495.7%	$-242.8K -111.4%	$2.1M
EPS (Diluted)	$-0.12 +62.5%	$-0.32 -68.4%	$-0.19 +54.8%	$-0.42 -1300.0%	$-0.03 -107.9%	$0.38
Total Assets	$42.5M -5.2%	$44.9M +15.9%	$38.7M +18.2%	$32.7M -4.6%	$34.3M +135.9%	$14.5M
Total Debt	$10.7M -46.9%	$20.2M +19.0%	$16.9M -9.1%	$18.6M +3.4%	$18.0M	—
Operating Cash Flow	$2.5M +260.3%	$-1.5M -761.2%	$233.5K +162.5%	$-373.4K -131.8%	$1.2M -59.5%	$2.9M

AI Insight: ICCC Financial Trends

Revenue inflection to $10M in Q1 2026 coincides with return to $2M net income and $4M operating cash flow, but sustained profitability remains unproven.

• Revenue grew 25% from $8M (Q4 2025) to $10M (Q1 2026), strongest quarterly result in dataset.

• Operating cash flow rebounded to $4M in Q1 2026 after three consecutive quarters of flat or negative OCF.

• Total debt decreased to $10M (Q1 2026) from peak of $21M (Q2 2024), strengthening balance sheet leverage.

⚠ Net income volatility persists: $2M profit in Q1 2026 follows $3M loss in Q4 2025. Consistency critical.

⚠ Revenue profile remains choppy; oscillated between $6M–$10M across eight quarters with no sustained growth trajectory.

AI Insight: ICCC Ratio Trends

ICCC swung to 19% operating margin and 26.7% ROE in Q1 2026 after near-breakeven Q4 2025, signaling a sharp operational inflection.

• Operating margin rebounded to 19.0% in Q1 2026 from -0.8% in Q4 2025; net profit margin jumped to 18.8% from -37.4%.

• ROE surged to 26.7% in Q1 2026 and ROIC climbed to 20.0%, the highest in the trailing dataset.

• Debt-to-equity fell to 0.35 in Q1 2026 from 0.90 in Q2 2024, indicating meaningful deleveraging.

⚠ Q4 2025 showed severe deterioration (NPM -37.4%, ROE -42.1%), raising questions on sustainability of Q1 2026 recovery.

⚠ TTM metrics lag Q1 2026 sharply (OpMargin 8.3%, ROE -1.9%), suggesting Q1 2026 may not yet reflect normalized earnings.

Get alerted when ICCC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IMMUCELL CORP /DE/ including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ICCC

VANGUARD CAPITAL MANAGEMENT LLC
$1.6M260,327 sh
MORGAN STANLEY
$1.4M221,716 sh
RENAISSANCE TECHNOLOGIES LLC
$960.8K151,789 sh
Cresset Asset Management, LLC
$856.2K135,267 sh
Bleichroeder LP
$643.1K101,594 sh
GEODE CAPITAL MANAGEMENT, LLC
$416.4K65,765 sh
DIMENSIONAL FUND ADVISORS LP
$354.7K56,030 sh
Steadtrust LLC
$344.2K54,370 sh
VANGUARD FIDUCIARY TRUST CO
$270.1K42,669 sh
Mesirow Financial Investment Management, Inc.
$268.9K42,481 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.6M	260,327
MORGAN STANLEY	$1.4M	221,716
RENAISSANCE TECHNOLOGIES LLC	$960.8K	151,789
Cresset Asset Management, LLC	$856.2K	135,267
Bleichroeder LP	$643.1K	101,594
GEODE CAPITAL MANAGEMENT, LLC	$416.4K	65,765
DIMENSIONAL FUND ADVISORS LP	$354.7K	56,030
Steadtrust LLC	$344.2K	54,370
VANGUARD FIDUCIARY TRUST CO	$270.1K	42,669
Mesirow Financial Investment Management, Inc.	$268.9K	42,481

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ICCC on your watchlist

Track score changes the day IMMUCELL CORP /DE/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ICCC a good stock to buy?

13F Pro's AI-powered analysis of IMMUCELL CORP /DE/ (ICCC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ICCC are available on the ICCC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ICCC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ICCC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IMMUCELL CORP /DE/'s investment landscape.